NASDAQ:CKPT Checkpoint Therapeutics (CKPT) Stock Price, News & Analysis $2.57 -0.09 (-3.38%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.52▼$2.7650-Day Range$1.79▼$2.6852-Week Range$1.30▼$3.62Volume471,088 shsAverage Volume477,643 shsMarket Capitalization$91.72 millionP/E RatioN/ADividend YieldN/APrice Target$22.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Checkpoint Therapeutics alerts: Email Address Checkpoint Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside779.4% Upside$22.60 Price TargetShort InterestBearish12.99% of Float Sold ShortDividend StrengthN/ASustainability-0.63Upright™ Environmental ScoreNews Sentiment0.44Based on 4 Articles This WeekInsider TradingSelling Shares$77,309 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.24) to $0.04 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.54 out of 5 starsMedical Sector291st out of 936 stocksPharmaceutical Preparations Industry133rd out of 436 stocks 3.5 Analyst's Opinion Consensus RatingCheckpoint Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCheckpoint Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Checkpoint Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.99% of the float of Checkpoint Therapeutics has been sold short.Short Interest Ratio / Days to CoverCheckpoint Therapeutics has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Checkpoint Therapeutics has recently increased by 2.87%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCheckpoint Therapeutics does not currently pay a dividend.Dividend GrowthCheckpoint Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCheckpoint Therapeutics has received a 62.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Checkpoint Therapeutics is -0.63. Previous Next 3.0 News and Social Media Coverage News SentimentCheckpoint Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Checkpoint Therapeutics this week, compared to 2 articles on an average week.Search Interest12 people have searched for CKPT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows3 people have added Checkpoint Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Checkpoint Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $77,309.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Checkpoint Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 22.00% of the stock of Checkpoint Therapeutics is held by institutions.Read more about Checkpoint Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Checkpoint Therapeutics are expected to grow in the coming year, from ($1.24) to $0.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Checkpoint Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Checkpoint Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Checkpoint Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Checkpoint Therapeutics Stock (NASDAQ:CKPT)Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Read More CKPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CKPT Stock News HeadlinesJune 29, 2024 | insidertrades.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray Sells 13,038 SharesJuly 25 at 6:42 PM | marketwatch.comCheckpoint Therapeutics Shares Rise After FDA Accepts Resubmission of CosibelimabJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 25 at 6:42 PM | markets.businessinsider.comCheckpoint Therapeutics Says FDA Accepted BLA Resubmission Of CosibelimabJuly 25 at 7:30 AM | globenewswire.comCheckpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell CarcinomaJuly 16, 2024 | americanbankingnews.comCheckpoint Therapeutics (NASDAQ:CKPT) Rating Reiterated by HC WainwrightJuly 15, 2024 | globenewswire.comGC Cell and Checkpoint Therapeutics Advance Collaborative Cancer ResearchJuly 2, 2024 | globenewswire.comCheckpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 2, 2024 | globenewswire.comCheckpoint Therapeutics Announces Biologics License Application Resubmission for CosibelimabJune 24, 2024 | globenewswire.comCheckpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA ResubmissionJune 5, 2024 | globenewswire.comCHECKPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating Checkpoint Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJune 3, 2024 | globenewswire.comCKPT DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action – CKPTJune 3, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Checkpoint Therapeutics, Inc. (CKPT)June 3, 2024 | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointJune 3, 2024 | globenewswire.comCKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 31, 2024 | prnewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointMay 30, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPTSee More Headlines Receive CKPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CKPT CUSIPN/A CIK1651407 Webwww.checkpointtx.com Phone(781) 652-4500FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$22.60 High Stock Price Target$47.00 Low Stock Price Target$4.00 Potential Upside/Downside+776.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,850,000.00 Net Margins-50,336.89% Pretax Margin-76,938.23% Return on EquityN/A Return on Assets-749.84% Debt Debt-to-Equity RatioN/A Current Ratio0.54 Quick Ratio0.54 Sales & Book Value Annual Sales$100,000.00 Price / Sales920.80 Cash FlowN/A Price / Cash FlowN/A Book Value($0.47) per share Price / Book-5.49Miscellaneous Outstanding Shares35,690,000Free Float34,937,000Market Cap$92.08 million OptionableOptionable Beta1.25 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. James F. Oliviero III (Age 48)C.F.A., President, CEO & Director Comp: $921.59kMr. William Garrett Gray (Age 37)CFO, Corporate Secretary & Treasurer Comp: $409.12kKey CompetitorsLeap TherapeuticsNASDAQ:LPTXVanda PharmaceuticalsNASDAQ:VNDAQ32 BioNASDAQ:QTTBXeris BiopharmaNASDAQ:XERSAC ImmuneNASDAQ:ACIUView All CompetitorsInsiders & Institutions180 Wealth Advisors LLCBought 42,750 shares on 7/17/2024Ownership: 0.120%James F Oliviero IIISold 24,610 sharesTotal: $50,450.50 ($2.05/share)William Garrett GraySold 13,038 sharesTotal: $26,858.28 ($2.06/share)B. Riley Wealth Advisors Inc.Sold 114,200 shares on 5/16/2024Ownership: 0.138%Vanguard Group Inc.Bought 369,586 shares on 5/10/2024Ownership: 2.572%View All Insider TransactionsView All Institutional Transactions CKPT Stock Analysis - Frequently Asked Questions How have CKPT shares performed this year? Checkpoint Therapeutics' stock was trading at $2.29 at the start of the year. Since then, CKPT stock has increased by 12.2% and is now trading at $2.57. View the best growth stocks for 2024 here. How were Checkpoint Therapeutics' earnings last quarter? Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) released its quarterly earnings data on Friday, May, 10th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.04. When did Checkpoint Therapeutics' stock split? Checkpoint Therapeutics shares reverse split on the morning of Sunday, December 4th 2022. The 1-10 reverse split was announced on Sunday, December 4th 2022. The number of shares owned by shareholders was adjusted after the market closes on Sunday, December 4th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Checkpoint Therapeutics' major shareholders? Checkpoint Therapeutics' top institutional investors include 180 Wealth Advisors LLC (0.12%). Insiders that own company stock include James F Oliviero III and William Garrett Gray. View institutional ownership trends. How do I buy shares of Checkpoint Therapeutics? Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Checkpoint Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV) and SCYNEXIS (SCYX). This page (NASDAQ:CKPT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkpoint Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.